Patents by Inventor Anthony Pope

Anthony Pope has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070148774
    Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.
    Type: Application
    Filed: November 1, 2006
    Publication date: June 28, 2007
    Applicants: MEDICAL RESEARCH COUNCIL, CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
    Inventors: John McCafferty, Anthony Pope, Kevin Johnson, Hendricus Mattheus Hoogenboom, Andrew Griffiths, Ronald Jackson, Kasper Holliger, James Marks, Timothy Clackson, David Chiswell, Gregory Winter, Timothy Bonnert
  • Publication number: 20050049403
    Abstract: Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF?) bind specifically isoforms TGF?2 and TGF?1 or both, preferentially compared with TGF?3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGF?2, neutralizing its activity, but does not bind the latent member.
    Type: Application
    Filed: July 23, 2003
    Publication date: March 3, 2005
    Inventors: Julia Thompson, Tristan Vaughan, Andrew Williams, Jonathan Green, Ronald Jackson, Louise Bacon, Kevin Johnson, Alison Wilton, Philip Tempest, Anthony Pope